A carregar...
Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
Therapeutic options for treating advanced melanoma are progressing rapidly. Although anti-programmed cell death 1 (PD1) antibodies (e.g., nivolumab, pembrolizumab) have been approved as first-line and anchor drugs, respectively, for treating advanced melanoma, the efficacy appears limited as we expe...
Na minha lista:
| Publicado no: | Front Med (Lausanne) |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6684946/ https://ncbi.nlm.nih.gov/pubmed/31417907 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2019.00174 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|